Extracorporeal removal for sepsis: Acting at the tissue level - The beginning of a new era for this treatment modality in septic shock

Critical Care Medicine

Volumn 32, Issue 3, 2004, Pages 896-897

  Honoré, Patrick M ^a   Matson, James R ^b  

^a St Pierre Para University Hospital   (Belgium)

^b MEDICAL CITY DALLAS HOSPITAL   (United States)

Author keywords

Control theory; Hemoadsorption; Hemofiltration; Immunomodulation; Nuclear factor B; Sepsis; Septic shock; Sorbents; Systems biology

Indexed keywords

ENDOTOXIN;

ACUTE DISEASE; ADSORPTION; CRITICAL ILLNESS; DEVICE; DISEASE COURSE; DISEASE DURATION; EDITORIAL; ENDOTOXEMIA; EVALUATION; EXTRACORPOREAL CIRCULATION; HEALTH STATUS; HUMAN; INFECTION CONTROL; INFLAMMATION; INJURY; LETHAL DOSE; LETHALITY; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; TIME; TREATMENT PLANNING;

ANIMALS; HEMOFILTRATION; INTERLEUKINS; NF-KAPPA B; RATS; SHOCK, SEPTIC;

EID: 1542719539     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000115262.31804.46     Document Type: Editorial

References (17)

1. Honore PM, Zydney A, Matson JR: High volume and high permeability haemofiltration for sepsis: The evidence and the key issues. Care of the Critically Ill 2003; 19:69-76
2. Callard R, George AJT, Stark J: Cytokines, chaos, and complexity. Immunity 1999; 11: 507-513
3. Neugebauer EAM, Willy C, Sauerland S: Complexity and non-linearity in shock research: Reductionism or synthesis? Shock 2001; 16:252-258
4. Sepsis Complete Guide to Therapeutic Trends: Septic Shock Treatment (B6A). PJB Publications, 2001, p 141
5. Csete ME, Doyle JC: Reverse engineering of biological complexity. Science 2002; 295: 1664-1669
6. Kellum JA, Song M, Venkataraman R: Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-κB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004; 32:801-805
7. Fry DE: Future directions in the treatment of SIRS and MODS. In: Multiple Organ Failure, Pathophysiology, Prevention, and Therapy. New York, Springer, 2000, p 683
8. Schetz M: Removal of cytokines in septic patients using continuous veno-venous hemodiafiltration. Crit Care Med 1994; 22: 715-716
9. Schetz M, Ferdinande P, Van den Berghe G, et al: Removal of pro-inflammatory cytokines with renal replacement therapy: Sense or nonsense? Intensive Care Med 1995; 21: 169-176
10. Banks W, Kastin A, Durham D: Bidirectional transport of interleukin-1 alpha across the blood-brain barrier. Brain Res Bull 1989; 23: 433-437
11. Banks W, Kastin A, Broadwell R: Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995; 2:241-248
12. Dowd C, Cooney C, Nugent M: Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. J Biol Chem 1999; 274:5236-5244
13. Banks W, Kastin A, Ehrensing C: Ciurnal uptake of circulating interleukin-1alpha by brain, spinal cord, testis and muscle. Neuroimmunomodulation 1998; 5:36-41
14. Goldfarb S, Golper T: Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 1994; 5:228-232
15. Lee P, Matson J, Pryor R, et al: continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993; 21: 914-924
16. Ronco C, Bellomo R, Homel P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomized trial. Lancet 2000; 356:26-30
17. Honore P, Matson J: Hemofiltration, adsorption, sieving and the challenge of sepsis therapy design. Crit Care 2002; 6:394-396